Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Capital Expenditures (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Capital Expenditures data on record, last reported at $3.5 million in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 3449.04% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $3.9 million, up 111.65%, while the annual FY2024 figure was $50000.0, 99.74% down from the prior year.
  • Capital Expenditures reached $3.5 million in Q3 2025 per GLUE's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $15.9 million in Q3 2023 and bottomed at -$3.0 million in Q2 2023.
  • Average Capital Expenditures over 3 years is $2.1 million, with a median of $983000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 104.8% in 2024, then soared 3449.04% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $1.7 million in 2023, then plummeted by 104.8% to -$81000.0 in 2024, then surged by 4400.0% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $3.5 million in Q3 2025, -$1.1 million in Q2 2025, and $1.6 million in Q1 2025.